Your browser doesn't support javascript.
loading
Clinical, Immunological, and Molecular Features of Typical and Atypical Severe Combined Immunodeficiency: Report of the Italian Primary Immunodeficiency Network.
Cirillo, Emilia; Cancrini, Caterina; Azzari, Chiara; Martino, Silvana; Martire, Baldassarre; Pession, Andrea; Tommasini, Alberto; Naviglio, Samuele; Finocchi, Andrea; Consolini, Rita; Pierani, Paolo; D'Alba, Irene; Putti, Maria Caterina; Marzollo, Antonio; Giardino, Giuliana; Prencipe, Rosaria; Esposito, Federica; Grasso, Fiorentino; Scarselli, Alessia; Di Matteo, Gigliola; Attardi, Enrico; Ricci, Silvia; Montin, Davide; Specchia, Fernando; Barzaghi, Federica; Cicalese, Maria Pia; Quaremba, Giuseppe; Lougaris, Vassilios; Giliani, Silvia; Locatelli, Franco; Rossi, Paolo; Aiuti, Alessandro; Badolato, Raffaele; Plebani, Alessandro; Pignata, Claudio.
Afiliación
  • Cirillo E; Pediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Cancrini C; Department of System of Medicine University of Rome Tor Vergata, Rome, Italy.
  • Azzari C; Unit of Immune and Infectious Disease, University Department of Pediatrics DPUO, Children's Hospital Bambino Gesù, Rome, Italy.
  • Martino S; Pediatric Immunology Unit, Anna Meyer Hospital, University of Florence, Florence, Italy.
  • Martire B; Department of Public Health and Pediatrics, Regina Margherita Children Hospital, University of Turin, Turin, Italy.
  • Pession A; Paediatric Hematology Oncology Unit, Policlinico-Giovanni XXII Hospital, University of Bari, Bari, Italy.
  • Tommasini A; Department of Pediatrics, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Naviglio S; Pediatric Hematology Oncology, Institute for Maternal and Child Health IRCCS "Burlo Garofolo", Trieste, Italy.
  • Finocchi A; Pediatric Hematology Oncology, Institute for Maternal and Child Health IRCCS "Burlo Garofolo", Trieste, Italy.
  • Consolini R; Department of System of Medicine University of Rome Tor Vergata, Rome, Italy.
  • Pierani P; Unit of Immune and Infectious Disease, University Department of Pediatrics DPUO, Children's Hospital Bambino Gesù, Rome, Italy.
  • D'Alba I; Section of Pediatrics Immunology and Rheumatology, Department of Pediatrics, University of Pisa, Pisa, Italy.
  • Putti MC; Division of Pediatric Hematology and Oncology, Ospedale G. Salesi, Ancona, Italy.
  • Marzollo A; Division of Pediatric Hematology and Oncology, Ospedale G. Salesi, Ancona, Italy.
  • Giardino G; Department of Child's and Woman's Health, Pediatric Oncology and Hematology, University of Padova, Padova, Italy.
  • Prencipe R; Department of Child's and Woman's Health, Pediatric Oncology and Hematology, University of Padova, Padova, Italy.
  • Esposito F; Pediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Grasso F; Pediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Scarselli A; Pediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Di Matteo G; Pediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Attardi E; Department of System of Medicine University of Rome Tor Vergata, Rome, Italy.
  • Ricci S; Unit of Immune and Infectious Disease, University Department of Pediatrics DPUO, Children's Hospital Bambino Gesù, Rome, Italy.
  • Montin D; Department of System of Medicine University of Rome Tor Vergata, Rome, Italy.
  • Specchia F; Unit of Immune and Infectious Disease, University Department of Pediatrics DPUO, Children's Hospital Bambino Gesù, Rome, Italy.
  • Barzaghi F; Department of System of Medicine University of Rome Tor Vergata, Rome, Italy.
  • Cicalese MP; Pediatric Immunology Unit, Anna Meyer Hospital, University of Florence, Florence, Italy.
  • Quaremba G; Department of Public Health and Pediatrics, Regina Margherita Children Hospital, University of Turin, Turin, Italy.
  • Lougaris V; Department of Pediatrics, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Giliani S; Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Locatelli F; Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Rossi P; Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
  • Aiuti A; Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia, Brescia, Italy.
  • Badolato R; A. Nocivelli Institute for Molecular Medicine, Department of Molecular and Translational Medicine, University of Brescia, and ASST Spedali Civili, Brescia, Italy.
  • Plebani A; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Rome, Italy.
  • Pignata C; Department of System of Medicine University of Rome Tor Vergata, Rome, Italy.
Front Immunol ; 10: 1908, 2019.
Article en En | MEDLINE | ID: mdl-31456805
ABSTRACT
Severe combined immunodeficiencies (SCIDs) are a group of inborn errors of the immune system, usually associated with severe or life-threatening infections. Due to the variability of clinical phenotypes, the diagnostic complexity and the heterogeneity of the genetic basis, they are often difficult to recognize, leading to a significant diagnostic delay (DD). Aim of this study is to define presenting signs and natural history of SCID in a large cohort of patients, prior to hematopoietic stem cell or gene therapies. To this purpose, we conducted a 30-year retro-prospective multicenter study within the Italian Primary Immunodeficiency Network. One hundred eleven patients, diagnosed as typical or atypical SCID according to the European Society for Immune Deficiencies criteria, were included. Patients were subsequently classified based on the genetic alteration, pathogenic mechanism and immunological classification. A positive relationship between the age at onset and the DD was found. SCID patients with later onset were identified only in the last decade of observation. Syndromic SCIDs represented 28% of the cohort. Eight percent of the subjects were diagnosed in Intensive Care Units. Fifty-three percent had an atypical phenotype and most of them exhibited a discordant genotype-immunophenotype. Pre-treatment mortality was higher in atypical and syndromic patients. Our study broadens the knowledge of clinical and laboratory manifestations and genotype/phenotype correlation in patients with SCID and may facilitate the diagnosis of both typical and atypical forms of the disease in countries where newborn screening programs have not yet been implemented.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunodeficiencia Combinada Grave Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Front Immunol Año: 2019 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunodeficiencia Combinada Grave Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Front Immunol Año: 2019 Tipo del documento: Article País de afiliación: Italia